Leprosy: An Overview (World Leprosy Day Guest Comment) by Aayushi Manocha & Apurv Manocha
IHRJ Volume 1 Issue 10 2017  
 
 
 
 
 
 
 
The disease called leprosy, once considered a 
stigma for the society, is also known by the name 
of Hansen’s disease after the scientist G. H. 
Armauer Hansen. The disease is a chronic 
bacterial infection caused by Mycobacterium 
leprae, discovered in 1873, by Hansen, and was 
indeed the first bacterium identified as causing 
disease in humans.1 
 
The disease was looked at as a ritual impurity, 
considering the infected people to be 
untrustworthy, unclean and morally corrupt. It 
was also considered to be highly contagious, 
which was just an untrue fear since the disease is 
not that contagious. Most common risk factors 
include low socio-economic status, poverty and 
close contact with the infected ones.  
 
The most common way of diagnosing it is by 
detecting acid-fast strain of bacterium in the skin 
biopsy sample or detecting DNA via a PCR test. 
The treatment of the disease depends on the type 
of disease: paucibacillary and multibacillary. 
Treatment includes a multidrug therapy of 2-3 
antibiotics namely clofazimine, dapsone, 
rifampicin etc. for a period of 12-24 months.2   
          
How is leprosy transmitted? 
Contrary to a popular belief of being highly 
contagious, the disease only spreads from human 
to human and exists more in the close contact with 
the cases and socio-economically backward 
groups. It is thought to occur through a cough or 
through nose secretions from an infected 
individual, i.e aerosol transmission. 
 
Causes of the disease 
As stated earlier, the infectious disease is known 
to be caused by an intracellular, aerobic, acid fast 
bacillus of Mycobacterium class, the M. leprae or 
M. lepromatosis. Two main types of the disease 
based on the number of bacteria have been 
understood, paucibacillary (five or fewer) and 
multibacillary (more than 5). They can be 
differentiated by the bacterial count and the 
number of hypoaesthetic skin patches. The 
organism cannot be cultured in vitro. Earlier, it 
used to be cultured in vivo in nine banded 
armadillo or mice since it is known to be occurring 
naturally in them. The organism being 
unculturable in the laboratory, is difficult to be 
identified under the Koch’s postulates. 
 
Signs and symptoms 
Leprosy is mainly a chronic granulomatous 
disease affecting peripheral nerves and mucosa of 
respiratory tract, mostly upper tract, skin lesions 
in form of patches etc. Presence of skin lesions like 
macules, papules, nodules along with thickened 
nerves further accompanied by paraesthesias and 
muscle weakness are the most common signs and 
symptoms. However, muscle weakness in absence 
of characteristic lesion and nerve thickness is not 
a reliable sign.3 
 
Classification 
Multiple classifications have been provided, 
however, the most followed is WHO classification 
and Ridley Jopling classification. Under the types 
of pauci and multibacillary, further classification 
into 5 types has been provided by Jopling, which 
includes, tuberculoid (TT), borderline tuberculoid 
(BT) under the paucibacillary group and 
borderline (BB), borderline lepromatous (BL) and 
lepromatous (LL) under multibacillary. Under 
WHO classification, an additional group of 
indeterminate (I) has also been identified. Of 
these, the tuberculoid (TT) has the best prognosis 
and the lepromatous (LL) has the worst.4  
 
How is the disease treated?  
Social stigma has been associated for much of 
history, which continues to be a barrier to self- 
reporting and early treatment. However, an early 
treatment is necessary for complete cure without 
any sequelae since the physical and neurological 
damage may be irreversible even if the disease is 
cured. The recommended treatment is a 
multidrug therapy (MDT) regime comprising of 
clofazimine, dapsone and rifampicin for a period 
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of 12 months for paucibacillary type and for 18- 24 
months for multibacillary type. This MDT regime 
is highly effective if observed well and the chances 
of relapse are low. Further, the resistance to the 
combination therapy is also less.5 
 
PREVENTION 
Few studies suggest that the BCG vaccine used for 
tuberculosis also provides a variable protection 
against leprosy. However, no vaccine has yet been 
discovered for leprosy itself. In India, the Leprosy 
Act was enacted initially in 1898, however, was 
repealed only after the MDT became widely 
available. In 1983, the National Leprosy 
Elimination Programme also came into light. 
However, India still accounts for more than half of 
the global disease burden.  
 
Despite the effective treatment and widespread 
awareness regarding the disease, the social stigma 
still prevails in endemic developing countries. 
Disbeliefs, religious connotations and lack of 
education continue to influence the social 
perceptions. Yet today, the disease accounts for 
untouchable status in many parts of poor 
countries. What is required of the society is a 
general widespread awareness keeping aside their 
connotations and beliefs, take a step forward for 
the help of  
needy and walk in the direction of progression and 
not regression to make sure the stigma is 
restrained.  
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